WO2017208136A1 - Pharmaceutical composition of dapagliflozin co-crystal - Google Patents
Pharmaceutical composition of dapagliflozin co-crystal Download PDFInfo
- Publication number
- WO2017208136A1 WO2017208136A1 PCT/IB2017/053155 IB2017053155W WO2017208136A1 WO 2017208136 A1 WO2017208136 A1 WO 2017208136A1 IB 2017053155 W IB2017053155 W IB 2017053155W WO 2017208136 A1 WO2017208136 A1 WO 2017208136A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- dapagliflozin
- oral pharmaceutical
- crystal
- citric acid
- Prior art date
Links
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical group C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title claims abstract description 63
- 229960003834 dapagliflozin Drugs 0.000 title claims abstract description 61
- 239000013078 crystal Substances 0.000 title claims abstract description 43
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 126
- 239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims description 130
- 239000008187 granular material Substances 0.000 claims description 22
- 239000003826 tablet Substances 0.000 claims description 18
- 239000000314 lubricant Substances 0.000 claims description 16
- 239000011230 binding agent Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 11
- 239000007884 disintegrant Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 239000007909 solid dosage form Substances 0.000 claims description 6
- 229940125708 antidiabetic agent Drugs 0.000 claims description 5
- 239000003472 antidiabetic agent Substances 0.000 claims description 5
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 4
- 239000007888 film coating Substances 0.000 claims description 4
- 238000009501 film coating Methods 0.000 claims description 4
- 238000003801 milling Methods 0.000 claims description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 4
- 239000008351 acetate buffer Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000007907 direct compression Methods 0.000 claims description 3
- 238000007908 dry granulation Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims description 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims description 2
- 229960002632 acarbose Drugs 0.000 claims description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 2
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims description 2
- 229960001667 alogliptin Drugs 0.000 claims description 2
- 229940110266 farxiga Drugs 0.000 claims description 2
- 229960004580 glibenclamide Drugs 0.000 claims description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 2
- 229960004346 glimepiride Drugs 0.000 claims description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 2
- 229960001381 glipizide Drugs 0.000 claims description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002397 linagliptin Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- 229960001110 miglitol Drugs 0.000 claims description 2
- 239000008185 minitablet Substances 0.000 claims description 2
- 229960000698 nateglinide Drugs 0.000 claims description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 229960005095 pioglitazone Drugs 0.000 claims description 2
- 229960003611 pramlintide Drugs 0.000 claims description 2
- 108010029667 pramlintide Proteins 0.000 claims description 2
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 claims description 2
- 229960002354 repaglinide Drugs 0.000 claims description 2
- 229960004586 rosiglitazone Drugs 0.000 claims description 2
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims description 2
- 229960004937 saxagliptin Drugs 0.000 claims description 2
- 108010033693 saxagliptin Proteins 0.000 claims description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims description 2
- 229960004034 sitagliptin Drugs 0.000 claims description 2
- 229960001729 voglibose Drugs 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000004090 dissolution Methods 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 10
- 239000013543 active substance Substances 0.000 description 10
- -1 e.g. Substances 0.000 description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 10
- 239000008108 microcrystalline cellulose Substances 0.000 description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 229960000913 crospovidone Drugs 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 229960001866 silicon dioxide Drugs 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- GOADIQFWSVMMRJ-UPGAGZFNSA-N dapagliflozin propanediol monohydrate Chemical compound O.C[C@H](O)CO.C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl GOADIQFWSVMMRJ-UPGAGZFNSA-N 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229960004463 (s)- propylene glycol Drugs 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- WOSFAOJJPMFTRL-UHFFFAOYSA-N propane-1,1-diol hydrate Chemical compound O.CCC(O)O WOSFAOJJPMFTRL-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates to oral pharmaceutical compositions comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients, and processes for their preparation. It further relates to a method of treating diabetes using said pharmaceutical compositions.
Description
PHARMACEUTICAL COMPOSITION OF DAPAGLIFLOZIN CO-CRYSTAL
Field of the Invention
The present disclosure relates to oral pharmaceutical compositions comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients, and processes for their preparation. The disclosure further relates to methods of treating diabetes using said pharmaceutical compositions.
Background of the Invention
Dapagliflozin is a SGLT2 inhibitor, chemically known as (25,3R,4R,55,6R)-2-[4- chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. Current commercially available formulations of dapagliflozin contain a propanediol (propylene glycol) monohydrate solvate of dapagliflozin as the active ingredient. The commercially available dapagliflozin is crystalline in nature. In contrast, dapagliflozin base can exist in amorphous form.
U.S. Patent No. 6,515,117 reports the compound dapagliflozin. U.S. Patent No. 7,919,598 reports a (S)-propylene glycol solvate of dapagliflozin and processes of preparation thereof.
U.S. Patent Nos. 7,851 ,502, 8,221 ,786, and 8,361 ,972 reports pharmaceutical compositions comprising dapagliflozin or dapagliflozin propylene glycol hydrate and specific excipients in given amounts. U.S. Patent No. 8,221 ,786 further reports pharmaceutical compositions in the form of a stock granulation comprising dapagliflozin propylene glycol hydrate and excipients.
PCT Publication No. WO 2012/163546 reports pharmaceutical compositions comprising cyclodextrin and dapagliflozin, in some embodiments as an inclusion complex.
PCT Publication No. WO 2015/011113 reports pharmaceutical compositions comprising amorphous solid dispersions of dapagliflozin or adsorbates of dapagliflozin with one or more pharmaceutically acceptable excipients.
PCT Publication No. WO 2015/104658 reports an amorphous form of
dapagliflozin and a solid dispersion comprising the same.
A novel co-crystal of dapagliflozin with citric acid was reported in PCT
Publication no. WO 2015/198227, which is hereby incorporated by reference in its
entirety. Such co-crystals were reported to have higher solubility, good storage stability, and better handling and processing ability due to their non-hygroscopic nature when compared to other polymorphic forms. Such co-crystals were reported to be useful in the treatment of patients with diabetes.
Summary of the Invention
The present disclosure relates to oral pharmaceutical compositions comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients. In some embodiments, the dapagliflozin citric acid co-crystal is present in an amount of from about 0.5% to about 25% in weight of the active moiety, based on the total weight of the composition. In some embodiments, the oral pharmaceutical composition of the present invention is prepared by a wet granulation process or by a dry process, such as direct compression and dry granulation.
Detailed Description of the Invention
The present disclosure provides oral pharmaceutical formulations comprising dapagliflozin citric acid co-crystal, especially a solid oral dosage form, such that the therapeutic benefits of the dapagliflozin may be delivered to a patient in need thereof. In some embodiments, the present invention provides a stable oral pharmaceutical formulation which is easy to manufacture, provides an acceptable dose uniformity, and provides a rapid dissolution profile. In some embodiments, the disclosure provides an oral pharmaceutical composition comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients.
According to some embodiments, the dapagliflozin citric acid co-crystal is from about 0.5% to about 25%, about 1% to about 20%, about 2% to about 15%, about 3% to about 10%, or about 4% to about 8% by weight of the total weight of the composition. According to some embodiments, the dapagliflozin citric acid co-crystal is from about 0.5% to about 25% by weight of the total weight of the composition. In some
embodiments, the dapagliflozin citric acid co-crystal is from about 4% to about 8% by weight of the total weight of the composition. Unless indicated otherwise, "%" and "percentage" when referring to amounts of active agent or excipients (e.g., diluents, disintegrants, lubricants, glidants, etc.) refers to wt%, e.g., the weight of the active agent or excipient relative to the weight of the total composition.
According to some embodiments, the dapagliflozin citric acid co-crystal is present in an amount of from about 1 mg to about 100 mg, about 2 mg to about 75 mg, about 3 mg to about 50 mg, about 4 mg to about 40 mg, about 5 mg to about 25 mg in the
composition, e.g., a single dosage form. In some embodiments, the dapagliflozin citric acid co-crystal is present in an amount of about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 12 mg, about 15 mg, about 20 mg, or about 25 mg in the composition. In some embodiments, the dapagliflozin citric acid co-crystal is in an effective amount in the pharmaceutical composition. The term an "effective amount" of an agent, as used herein, is that amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, an "effective amount" depends upon the context in which it is being applied.
In some embodiments, the pharmaceutically acceptable excipients are selected from one or more of a diluent, a binder, a disintegrant, a lubricant, and mixtures thereof. In some embodiments, the pharmaceutical composition is free of binder.
In some embodiments, the disclosure of the present inventions provides compositions with increase stability over time, increased stability at various temperatures and/or increased stability at various humidity levels. For example, in some embodiments, the present disclosure provides compositions stable for 3 months, 6 months, 9 months, 12 months, 15 months, 18 months or 24 months when stored at 30°C at 65% relative humidity ("RH"). In some embodiments, the present disclosure provides compositions stable for 3 months, 6 months, 9 months, 12 months, 15 months, 18 months or 24 months when stored at 40°C at 75% RH.
In some embodiments, the compositions are stable for three months when stored at 30°C and 65% relative humidity ("RH"). In some embodiments, the compositions stable for three months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for three months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for three months when stored at 40°C and 75% RH and when stored at 40°C and 75% RH.
In some embodiments, the compositions are stable for six months when stored at 30°C and 65% relative humidity ("RH"). In some embodiments, the compositions are stable for six months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for six months when stored at 40°C and 75% RH. In some
embodiments, the compositions are stable for six months when stored at 40°C and 75% RH and when stored at 40°C and 75% RH.
In some embodiments, the compositions are stable for nine months when stored at 30°C and 65% relative humidity ("RH"). In some embodiments, the compositions are stable for nine months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for nine months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for nine months when stored at 40°C and 75% RH and when stored at 40°C and 75% RH.
In some embodiments, the compositions are stable for twelve months when stored at 30°C and 65% relative humidity ("RH"). In some embodiments, the compositions are stable for twelve months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for twelve months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for twelve months when stored at 40°C and 75% RH and when stored at 40°C and 75% RH.
In some embodiments, the term " stable " refers to a pharmaceutical composition, e.g., dosage form, in which at least 85%, at least 90%, at least 95% or at least 96% of the active agent, e.g., dapagliflozin, remains active at the designated time period compared to the original amount of active agent. In some embodiments, the term "stable" refers to a pharmaceutical composition comprising impurities less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, or less than 0.2% wt/wt as determined by HPLC at the termination of the designated time period compared to the original amount of active agent as determined by HPLC.
In some embodiments, the disclosure provides for a pharmaceutical composition having a rapidly dissolving in vitro dissolution profile. In some embodiments as described herein, dissolution is determined in 1000 mL pH 4.5 acetate buffer using USP apparatus Type-I at 60 RPM, at 37°C ±0.5°C. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 10 minutes, not less than 80%, 85%, 90%, or 92% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 10 minutes, not less than 85% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 10 minutes, not less than 90% of drug is released.
In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 15 minutes, not less than 80%, 85%, 90%, 92% or 94% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 15 minutes, not less than 85% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 15 minutes, not less than 92% of drug is released.
In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 30 minutes, not less than 90%, 92%, 94%, 96% or 98% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 30 minutes, not less than 95% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 30 minutes, not less than 98% of drug is released.
In some embodiments, the disclosure provides for a rapidly dissolving, stable pharmaceutical composition, e.g., dosage form, comprising:
(i) from about 1% to about 25% dapagliflozin citric acid co-crystal;
(ii) from about 40% to about 90% diluent;
(iii) from about 2% to about 20% disintegrant;
(iv) from about 0.5% to about 5% glidant; and
(v) about 0.1% to about 3% lubricant,
wherein the total composition does not exceed 100%.
In some embodiments, the disclosure provides for a rapidly dissolving, stable pharmaceutical composition, e.g., dosage form, comprising:
(i) from about 1% to about 25% dapagliflozin citric acid co-crystal;
(ii) from about 40% to about 90% microcrystalline cellulose, lactose, or
combinations thereof;
(iii) from about 2% to about 20% crospovidone;
(iv) from about 0.5% to about 5% silicon dioxide; and
(v) about 0.1% to about 3% magnesium stearate, sodium stearyl fumarate, or combinations thereof,
wherein the total composition does not exceed 100%.
In some embodiments, the disclosure provides for a rapidly dissolving, stable pharmaceutical composition comprising an intragranular part, and an extragranular part, the intragranular part comprising:
(i) from about 1% to about 25% dapagliflozin citric acid co-crystal;
(ϋ) from about 40% to about 90% diluent;
(iii) from about 2% to about 20% disintegrant;
(iv) from about 0.5% to about 5% glidant; and
(v) from about 0.1% to about 3% lubricant,
wherein the intragranular part does not exceed 100%; and the extragranular part comprising:
(i) from about 60% to about 95% diluent;
(ii) from about 5% to about 30% disintegrant;
(iii) from about 1% to about 10% glidant; and
(iv) from about 0.1% to about 3% lubricant,
wherein the extragranular part does not exceed 100%; and wherein the composition comprises about 60% to about 95% intragranular part, and about 5% to about 40% extragranular part. In some embodiments, the composition comprises about 75% to about 90% intragranular part, and about 10% to about 25% extragranular part, or about 80% to intragranular part, and about 20% extragranular part. The term "intragranular" refers to granules comprising the active agent, and the term "extragranular" refers to granules not comprising the active agent.
In some embodiments, present disclosure provides a process for making an oral pharmaceutical composition comprising:
(a) mixing dapagliflozin citric acid co-crystal with one or more pharmaceutically acceptable excipients to form a blend; and
(b) directly compressing the blend of (a) into a solid dosage form.
In some embodiments, the present disclosure provides a process for making an oral pharmaceutical composition comprising:
(a) mixing dapagliflozin citric acid co-crystal with one or more pharmaceutically acceptable excipients to form a blend;
(b) compacting the blend of (a) into a slug or a compact;
(c) milling the slug or compact of (b) into granules;
(d) optionally mixing the granules of (c) with further pharmaceutically acceptable excipients to form a final blend; and
(e) optionally compressing the final blend of (d) into a solid dosage form.
In some embodiments, the present disclosure provides a process for making an oral pharmaceutical composition comprising:
(a) mixing dapagliflozin citric acid co-crystal with one or more pharmaceutically acceptable excipients to form a blend;
(b) granulating the blend of (a) with a granulating liquid to obtain granules;
(c) drying the granules of (b) to obtain dried granules;
(d) optionally milling the dried granules of (c);
(e) adding at least one lubricant to the granules of (c) or the milled material of (d), and optionally mixing with further pharmaceutically acceptable excipients to form a final blend; and
(f) optionally compressing the final blend of (d) into a solid dosage form.
In some embodiments, the present disclosure provides a method of treating diabetes by administering an oral pharmaceutical composition as described herein comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients.
According to one embodiment, the method of treatment further comprises administration of an additional anti-diabetic agent.
The term "pharmaceutical composition," as used herein, includes solid dosage forms such as powder, pellets, mini-tablets, granules, tablets, capsules, and the like. In some embodiments, the composition is in the form of powder, granules, tablets, caplet, gelcap, or capsules.
The term "dapagliflozin citric acid co-crystal," as used herein, refers to a stoichiometric multi component system comprising dapagliflozin base and citric acid in a stoichiometric ratio of 1 : 1 and connected by non-covalent interactions. In some embodiments, the term "dapagliflozin citric acid co-crystal" is as described in
WO 2015/198227, incorporated herein in its entirely. In some embodiments, the
dapagliflozin citric acid co-crystal is present in the composition in an amount of from about 0.5% to about 25% by weight based on the total weight of the composition. One of skill in the art will appreciate that not 100% of the dapagliflozin citric acid necessarily will be in crystalline form. Thus, as used herein, in some embodiments the term "dapagliflozin citric acid co-crystal" includes a composition wherein at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least 98% or at least 99% of the dapagliflozin citric acid in the composition is in crystalline form.
The term "anti-diabetic agents," as used herein, includes, but is not limited to metformin, pioglitazone, rosiglitazone, sitagliptin, linagliptin, saxagliptin, alogliptin, pramlintide, repaglinide, nateglinide, acarbose, miglitol, glimepiride, glyburide, glipizide, and voglibose.
The term "about," as used herein, refers to any value which lies within the range defined by a variation of up to ±10% of the value.
The term "active moiety," as used herein, refers to the dapagliflozin base. For example, 14.7 mg of dapagliflozin citric acid co-crystal corresponds to 10 mg of dapagliflozin base.
The term "pharmaceutically acceptable excipients," as used herein, includes diluents, binders, disintegrants, lubricants, glidants, and mixtures thereof.
Various diluents can be used. In some embodiments, suitable diluents are selected from the group consisting of lactose, e.g., lactose anhydrous and lactose monohydrate; cellulose, e.g. , microcrystalline cellulose, co-processed microcrystalline cellulose, and powdered cellulose; starch, e.g., pregelatinized starch, maize starch, rice starch, potato starch, and wheat starch; sugar alcohols, e.g., mannitol, sorbitol, xylitol, and erythritol; inorganic salts, e.g., calcium carbonate, calcium phosphate, calcium sulfate, dibasic calcium phosphate, dibasic calcium phosphate anhydrate, dibasic calcium phosphate dihydrate, and tribasic calcium phosphate; and mixtures thereof. The diluents can be present in an amount of from about 20% to about 98% by weight of the composition, preferably from about 30% to about 95% by weight of the composition. In some embodiments, the diluents are about 60% to about 90% by weight of the composition, about 70% to about 90% by weight of the composition, or about 80% to about 90% by weight of the composition.
Various binders can be used according to the present disclosure. In some embodiments, suitable binders are selected from the group consisting of povidone, copovidone, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, carboxymethyl cellulose sodium, xanthan gum, gum acacia, gum arabic, tragacanth, corn starch, modified corn starch, maize starch, pregelatinized starch, methacrylates, carboxyvinyl polymers, waxes, and mixtures thereof. The binder can be present in an amount of from about 0% to about 30% by weight of the composition, preferably from about 0% to about 20% by weight of the composition. In some embodiments, the binders are about 0% to about 10% by weight of the composition, about 0% to about 5% by weight of the composition, or about 0% to about 1% by weight of the composition. In some embodiments, no binder is present in the compositions, i.e., the composition comprises 0% binder.
Various disintegrants can be used according to the present disclosure. In some embodiments, suitable disintegrants are selected from the group consisting of
croscarmellose sodium, hydroxypropyl cellulose, crospovidone, low substituted hydroxypropyl cellulose, microcrystalline cellulose, carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, starch, corn starch, pregelatinized starch, modified starch, sodium starch glycolate, carboxymethyl starch, poly aery lates, and mixtures thereof. The disintegrant can be present in an amount of from about 0% to about 30% by weight of the composition, preferably from about 0% to about 20% by weight of the composition. In some embodiments, the disintegrants are about 1% to about 10% by weight of the composition, about 1% to about 5% by weight of the composition, or about 5% to about 7% by weight of the composition.
Various lubricants can be used according to the present disclosure. In some embodiments, suitable lubricants are selected from the group consisting of stearic acid, magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, polyethylene glycol, talc, hydrogenated vegetable oils, fatty acids, waxes, and mixtures thereof. The lubricant can be present in an amount of from about 0.1% to about 10% by weight of the composition, preferably from about 0.1% to about 5% by weight of the composition. In some embodiments, the lubricant is about 0.01% to about 5% by weight of the
composition, about 0.1 % to about 2% by weight of the composition, or about 1 % to about 2% by weight of the composition.
Various glidants can be used according to the present disclosure. In some embodiments, suitable glidants or anti-sticking agents are selected from the group consisting of talc, silicon dioxide, colloidal silicon dioxide (colloidal anhydrous silica), calcium silicate, magnesium silicate, hydrated silica, and mixtures thereof. The glidant can be present in an amount of from about 0.1% to about 10% by weight of the composition, preferably from about 0.1% to about 5% by weight of the composition. In some embodiments, the lubricant is about 0% to about 5% by weight of the composition, about 0.1% to about 5% by weight of the composition, or about 1% to about 2% by weight of the composition.
The oral pharmaceutical composition may be prepared by a wet granulation process or by a dry process such as direct compression and dry granulation. Preferably, the pharmaceutical composition is prepared by a dry process. The composition can have a coating, or optionally can be uncoated. In some embodiments, the oral pharmaceutical composition is further film-coated using techniques well known in the art, such as spray coating in a conventional coating pan or dip coating. The film coat comprises film- forming polymers and one or more coating additives. The target weight gain after the coating can vary between 1% and 10% by weight of the uncoated composition, between 1.5% and 6% by weight of the uncoated composition, or between 2% and 4% by weight of the uncoated composition.
Suitable film- forming polymers are selected from the group comprising cellulose derivatives, e.g., methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethylethyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, and ethyl cellulose; vinyl polymers, e.g. ,
polyvinylpyrrolidones; acrylic polymers; and mixtures thereof. Alternatively, commercially available coating compositions comprising film- forming polymers marketed under various trade names, e.g., Opadry®, may be used for coating.
In some embodiments, the film-coating provides for immediate release, extended release, sustained release, delayed release, enteric release, or intestinal release of the active agent, e.g., dapagliflozin citric acid co-crystal, to the subject in which the dosage form was administered. In some embodiments, the film-coating provides for immediate release of the active agent.
As used herein, the term "delayed release" refers to a pharmaceutical preparation, e.g., an orally administered formulation, which passes through the stomach substantially intact and dissolves in the small and/or large intestine (e.g., the colon). In some embodiments, delayed release of the active agent (e.g., dapagliflozin citric acid co-crystal as described herein) results from the use of an enteric coating of an oral medication (e.g., an oral dosage form). The terms "extended release" or "sustained release"
interchangeably refer to a drug formulation that provides for gradual release of a drug over an extended period of time, e.g., 6-12 hours or more, compared to an immediate release formulation of the same drug. In some embodiments, although not necessarily, extended release results in substantially constant blood levels of a drug over an extended time period that are within therapeutic levels. As used herein, the terms "enteric release" refer to pharmaceutical compositions, e.g., oral dosage forms, for oral administration able to provide protection from dissolution in the high acid (low pH) environment of the stomach. Enteric formulations can be obtained by, for example, incorporating into the
pharmaceutical composition a polymer resistant to dissolution in gastric juices. In some embodiments, the polymers have an optimum pH for dissolution in the range of approximately 5.0 to 7.0 ("pH sensitive polymers").
The film coating", "film" or "coating additives comprise one or more of plasticizers, glidants or flow regulators, lubricants, coloring agents, and opacifiers.
Suitable plasticizers are selected from the group comprising castor oil, diacetylated monoglycerides, dibutyl sebacate, diethyl phthalate, glycerin, polyethylene glycols, propylene glycols, triacetin, triethyl citrate, and mixtures thereof. An opacifier, like titanium dioxide, may also be present in the coating.
Examples of solvents used for preparing the coating solution are selected from purified water, methyl alcohol, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, acetone, acetonitrile, chloroform, methylene chloride, and mixtures thereof.
The oral pharmaceutical composition will be bioequivalent to the marketed formulation of dapagliflozin (as propanediol monohydrate) available under the brand name Farxiga® (AstraZeneca, United Kingdom).
The oral pharmaceutical composition is used for treating diabetes, particularly Type
II diabetes. The pharmaceutical composition may be administered in combination with other anti-diabetic agents. Various regimens are known to those in the art. In some
embodiments, the oral pharmaceutical composition is administered once daily. In some embodiments, the oral pharmaceutical composition is administered twice daily. In some embodiments, the oral pharmaceutical composition is administered every other day. One of skill in the art can also appreciate that in some embodiments, the pharmaceutical composition can be divided (e.g., split in half), with one or more of the divided parts taken at the same time or at different times.
The present invention is illustrated below by reference to the following examples. However, one skilled in the art will appreciate that the specific methods and results discussed are merely illustrative of the invention, and not to be construed as limiting the invention, as many variations thereof are possible without departing from the spirit and scope of the invention.
EXAMPLES
Example 1:
Procedure:
1. Dapagliflozin citric acid co-crystal, microcrystalline cellulose, lactose,
crospovidone, and silicon dioxide were mixed in a blender.
2. Magnesium stearate was added to the above blend in the blender and mixed.
3. The blend of step 2 was compressed into tablets.
4. An Opadry® dispersion was prepared, and the tablets of step 3 were coated to a weight build-up of 2% to 4% w/w.
Dissolution Study
The tablets of Example 1 were subjected to an in-vitro dissolution study in 1000 mL of pH 4.5 acetate buffer at 37°C ±0.5° C for 30 minutes, using USP apparatus Type-I at 60 RPM. The results are given in Table 1 below:
Table 1. Dissolution profile of tablets of Example 1
Example 2:
Procedure:
1. Dapagliflozin citric acid co-crystal, microcrystalline cellulose, lactose,
crospovidone and silicon dioxide were mixed in a blender.
2. Magnesium stearate was added to the above blend in the blender and mixed.
3. The blend of step 2 was compressed into tablets.
4. An Opadry® dispersion was prepared, and the tablets of step 3 were coated to a weight build-up of 2% to 4% w/w.
Stability Data:
Tablets prepared according to Example 2 were stored at 30°C and 65% RH and at
40°C and 75% RH for six months, and were then tested by HPLC to determine the amount of total impurities. The stability data is given in Table 2.
Table 2. Stability data of the tablets of Example 2.
Examples 3-4:
Procedure:
Blend Dapagliflozin citric acid co-crystal, microcrystalline cellulose, lactose, povidone, crospovidone, and silicon dioxide in a blender.
Add Magnesium stearate or sodium stearyl fumarate to the above blend in the blender and mixed.
Compress the blend of step 2 into tablets.
Prepare Opadry® dispersion and coat the tablets of step 3 to a weight build-up of 2% to 4% w/w.
Example 5:
Procedure:
1. Blend Dapagliflozin citric acid co-crystal, microcrystalline cellulose, lactose anhydrous, crospovidone, and silicon dioxide in a blender.
2. Compact the blend of step 1 followed by milling to obtain granules.
3. Blend the extra granular excipients with the granules obtained in step 2.
4. Compress the blend of step 3 into tablets.
5. Prepare Opadry® dispersion, and coat the tablets of step 4 with the Opadry® dispersion to a weight build-up of 2% to 4% w/w.
Examples 6-8:
Procedure:
1. Blend lactose anhydrous/monohydrate, microcrystalline cellulose, and
dapagliflozin citric acid co-crystal in a blender.
2. Dissolve Hydroxypropyl cellulose or hydroxypropylmethyl cellulose or povidone in a solvent mixture or purified water to obtain a binder solution.
3. Granulate the material of step 1 with the binder solution of step 2.
4. Dry and mill the granules obtained in step 3.
5. Add extragranular microcrystalline cellulose and crospovidone to the granules of step 4, and mixed.
6. Add colloidal anhydrous silica and magnesium stearate to the material of step 5, and mixed.
7. Compress the blend of step 6 into tablets.
8. Prepare Opadry® dispersion and coat the tablets of step 7 with the Opadry® dispersion to a weight build-up of 2% to 4% w/w.
Claims
1. An oral pharmaceutical composition comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients, wherein the dapagliflozin citric acid co-crystal is from about 0.5% to about 25% by weight of the total weight of the composition.
2. The oral pharmaceutical composition according to claim 1 , wherein the dapagliflozin citric acid co-crystal in the pharmaceutical composition is from about 1 mg to about 100 mg.
3. The oral pharmaceutical composition according to any one of claims 1 to 2, wherein the pharmaceutically acceptable excipients are selected from one or more of diluents, binders, disintegrants, lubricants, and mixtures thereof.
4. The oral pharmaceutical composition according to any one of claims 1 to 3, wherein the composition is free of binder.
5. The oral pharmaceutical composition according to any one of claims 1 to 4, wherein the composition is in the form of powder, pellets, mini-tablets, granules, tablets, or capsules.
6. The oral pharmaceutical composition according to any one of claims 1 to 5, wherein the composition further comprises a film-coating.
7. The oral pharmaceutical composition according to any one of claims 1 to 6, wherein the composition is stable for six months when stored at 30°C and 65% RH or 40°C and 75% RH.
8. The oral pharmaceutical composition according to any one of claims 1 to 7, wherein the composition exhibits a rapidly dissolving in-vitro release profile.
9. The oral pharmaceutical composition according to claim 8, wherein the composition releases not less than 85% of the drug in 15 minutes, when tested in 1000 mL pH 4.5 acetate buffer using USP apparatus Type-I at 60 RPM, at 37°C ±0.5°C.
10. The oral pharmaceutical composition according to any one of claims 1 to 9, wherein the composition is bioequivalent to the marketed Farxiga® tablet.
11. The oral pharmaceutical composition according to any one of claims 1 to 10, wherein the composition is prepared by a wet granulation process.
12. The oral pharmaceutical composition according to any one of claims 1 to 10, wherein the composition is prepared by a dry process selected from direct compression and dry granulation.
13. A process of preparing an oral pharmaceutical composition comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients, wherein the process comprises:
(a) mixing dapagliflozin citric acid co-crystal with one or more pharmaceutically acceptable excipients to form a blend; and
(b) directly compressing the blend of (a) into a solid dosage form.
14. A process of preparing an oral pharmaceutical composition comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients, wherein the process comprises:
(a) mixing dapagliflozin citric acid co-crystal with one or more pharmaceutically acceptable excipients to form a blend;
(b) granulating the blend of (a) with a granulating liquid to obtain granules; (c) drying the granules of (b) to obtain dried granules;
(d) adding at least one lubricant to the dried granules of step (c) to form a final blend.
15. The process of claim 14, further comprising milling the dried granules of (c).
16. The process of any one of claims 14 or 15, comprising further mixing additional pharmaceutical excipients with the lubricant of (d) to form the final blend.
17. The process of any one of claims 14 to 16, further comprising compressing the final blend of (d) into a solid dosage form.
18. A method of the treatment of type 2 diabetes mellitus, said method comprising
administering an oral pharmaceutical composition according to any one of claims 1 to 17 to a subject in need thereof.
19. The method according to claim 18, wherein method of treatment further comprises administration of an additional anti-diabetic agent.
20. The method according to claim 19, wherein the additional anti-diabetic agent is selected from the group consisting of metformin, pioglitazone, rosiglitazone, sitagliptin, linagliptin, saxagliptin, alogliptin, pramlintide, repaglinide, nateglinide, acarbose, miglitol, glimepiride, glyburide, glipizide, and voglibose.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237012428A KR20230056789A (en) | 2016-05-30 | 2017-05-30 | Pharmaceutical composition of dapagliflozin co-crystal |
KR1020187036843A KR20190015329A (en) | 2016-05-30 | 2017-05-30 | A pharmaceutical composition of a dapagliflozin co-crystal |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201611018449 | 2016-05-30 | ||
IN201611018449 | 2016-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017208136A1 true WO2017208136A1 (en) | 2017-12-07 |
Family
ID=60478087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2017/053155 WO2017208136A1 (en) | 2016-05-30 | 2017-05-30 | Pharmaceutical composition of dapagliflozin co-crystal |
Country Status (2)
Country | Link |
---|---|
KR (2) | KR20190015329A (en) |
WO (1) | WO2017208136A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111494328A (en) * | 2020-04-07 | 2020-08-07 | 乐普制药科技有限公司 | Osmotic pump tablet containing acarbose and dapagliflozin and preparation method thereof |
CN112206216A (en) * | 2020-10-15 | 2021-01-12 | 江西华士药业有限公司 | Preparation method of sustained-release potent dapagliflozin |
WO2021176096A1 (en) * | 2020-03-05 | 2021-09-10 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising sglt2 inhibitor |
CN113943282A (en) * | 2020-07-15 | 2022-01-18 | 中国医学科学院药物研究所 | Pioglitazone hydrochloride and aminosalicylic acid eutectic crystal, preparation method, composition and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120041069A1 (en) * | 2008-10-17 | 2012-02-16 | Nectid Inc. | Sglt2 inhibitor dosage forms |
US20140249098A1 (en) * | 2011-06-03 | 2014-09-04 | Ratiopharm Gmbh | Pharmaceutical Composition Comprising Dapagliflozin and Cyclodextrin |
US20140343010A1 (en) * | 2013-04-29 | 2014-11-20 | Mapi Pharma Ltd. | Co-crystals of dapagliflozin |
WO2015198227A1 (en) * | 2014-06-23 | 2015-12-30 | Sun Pharmaceutical Industries Limited | Co-crystal of dapagliflozin with citric acid |
-
2017
- 2017-05-30 KR KR1020187036843A patent/KR20190015329A/en not_active Application Discontinuation
- 2017-05-30 KR KR1020237012428A patent/KR20230056789A/en not_active Application Discontinuation
- 2017-05-30 WO PCT/IB2017/053155 patent/WO2017208136A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120041069A1 (en) * | 2008-10-17 | 2012-02-16 | Nectid Inc. | Sglt2 inhibitor dosage forms |
US20140249098A1 (en) * | 2011-06-03 | 2014-09-04 | Ratiopharm Gmbh | Pharmaceutical Composition Comprising Dapagliflozin and Cyclodextrin |
US20140343010A1 (en) * | 2013-04-29 | 2014-11-20 | Mapi Pharma Ltd. | Co-crystals of dapagliflozin |
WO2015198227A1 (en) * | 2014-06-23 | 2015-12-30 | Sun Pharmaceutical Industries Limited | Co-crystal of dapagliflozin with citric acid |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021176096A1 (en) * | 2020-03-05 | 2021-09-10 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising sglt2 inhibitor |
CN111494328A (en) * | 2020-04-07 | 2020-08-07 | 乐普制药科技有限公司 | Osmotic pump tablet containing acarbose and dapagliflozin and preparation method thereof |
CN113943282A (en) * | 2020-07-15 | 2022-01-18 | 中国医学科学院药物研究所 | Pioglitazone hydrochloride and aminosalicylic acid eutectic crystal, preparation method, composition and application thereof |
CN113943282B (en) * | 2020-07-15 | 2023-12-19 | 中国医学科学院药物研究所 | Pioglitazone hydrochloride para-aminosalicylic acid eutectic crystal, preparation method, composition and application thereof |
CN112206216A (en) * | 2020-10-15 | 2021-01-12 | 江西华士药业有限公司 | Preparation method of sustained-release potent dapagliflozin |
Also Published As
Publication number | Publication date |
---|---|
KR20190015329A (en) | 2019-02-13 |
KR20230056789A (en) | 2023-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5788331B2 (en) | Pharmaceutical formulations comprising one or more fumarate esters in an erosion matrix | |
JP6976946B2 (en) | A pharmaceutical composition containing an inhibitor of URAT1 having strong bioactivity. | |
BR112020024203A2 (en) | pharmaceutical combination, composition and formulation containing glucokinase activator and a-glucosidase inhibitor, methods of preparation and use thereof | |
WO2015128853A1 (en) | Dapagliflozin compositions | |
HU231114B1 (en) | Pharmaceutical preparations containing mycophenolic acid or mycophenolate | |
WO2017208136A1 (en) | Pharmaceutical composition of dapagliflozin co-crystal | |
WO2014080384A1 (en) | Pharmaceutical composition of linagliptin | |
US20070104789A1 (en) | Gastro-resistant and ethanol-resistant controlled-release formulations comprising hydromorphone | |
JP2015522653A (en) | Pharmaceutical composition of proton pump inhibitor | |
WO2011051967A2 (en) | Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof | |
US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
JP2019512537A (en) | Pharmaceutical composition of dapagliflozin | |
US9132092B1 (en) | Pharmaceutical composition of doxycycline | |
EP3038607A2 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir | |
US11331273B2 (en) | Film-coated tablet having high chemical stability of active ingredient | |
US9561242B2 (en) | Doxycycline composition | |
US20080081069A1 (en) | Novel controlled release formulations of divalproex sodium | |
US20110159092A1 (en) | Extended release pharmaceutical composition comprising linezolid and process for preparing the same | |
US20150250734A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
US20100310652A1 (en) | Coated extended release pharmaceutical compositions of levetiracetam | |
WO2017037645A1 (en) | Stable pharmaceutical formulations of teriflunomide | |
US20160143923A1 (en) | Low dose pharmaceutical composition of doxycycline | |
US9566287B2 (en) | Pharmaceutical composition of doxycycline with reduced food effect | |
US20120121722A1 (en) | Atazanavir formulations | |
WO2014096983A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17805972 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187036843 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17805972 Country of ref document: EP Kind code of ref document: A1 |